KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other Accumulated Expenses (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Other Accumulated Expenses data on record, last reported at $10.2 million in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 88.61% year-over-year to $10.2 million; the TTM value through Sep 2025 reached $10.2 million, up 88.61%, while the annual FY2024 figure was $12.6 million, 29.13% down from the prior year.
  • Other Accumulated Expenses reached $10.2 million in Q3 2025 per SRPT's latest filing, up from $5.9 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $19.0 million in Q3 2021 and bottomed at $3.9 million in Q1 2021.
  • Average Other Accumulated Expenses over 5 years is $11.8 million, with a median of $13.0 million recorded in 2025.
  • The widest YoY moves for Other Accumulated Expenses: up 351.17% in 2022, down 77.16% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $15.1 million in 2021, then tumbled by 64.69% to $5.3 million in 2022, then surged by 235.81% to $17.8 million in 2023, then dropped by 29.13% to $12.6 million in 2024, then decreased by 19.6% to $10.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $10.2 million in Q3 2025, $5.9 million in Q2 2025, and $13.0 million in Q1 2025.